Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/23/14 | $17,000,000 | Series A |
Atlas Venture Novartis Venture Funds Partners Innovation Fund Pfizer Strategic Investments Group | undisclosed |
| 10/07/15 | $6,250,000 | Series A |
Remeditex Ventures | undisclosed |
